Davunetide

Do not turn a name’s origin into a localization or function claim. Preserve the specific evidence connecting sequence, detection and response.

NAP’s preclinical hypothesis concerns the microtubule system. Animal behavioral or protein-accumulation changes do not alone prove direct molecular interaction or necessarily explain a human trial’s outcome.

Synthetic research peptide

In mice overexpressing human alpha-synuclein, NAP was associated with fewer motor-test errors and differences in proteinase-K-resistant inclusions. Findings concern that genetic construct and those outcomes, not every disease involving altered neuronal proteins.

The randomized trial in people with progressive supranuclear palsy found no placebo difference in primary progression and daily-activity endpoints. Preclinical findings therefore cannot be presented as confirmation of human benefit in that disease.

The mouse study and human trial examined different pathological systems and variables, so they are not direct replications. A rigorous account separates mechanistic plausibility, animal behavior and human outcomes, retaining the negative finding without turning it into a conclusion about every possible experimental context.